# Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia

> **NIH NIH K08** · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $206,076

## Abstract

PROJECT SUMMARY/ABSTRACT
Therapeutic modulation of dysregulated metabolism has emerged as a successful therapeutic strategy for acute
myeloid leukemia (AML) harboring oncogenic isocitrate dehydrogenase (IDH) mutations. Inhibition of IDH results
in terminal myeloid differentiation of leukemic blasts and led to FDA-approval of IDH1 and IDH2 inhibitors in
AML. However, there are currently no metabolism-directed therapies for IDH wild-type AML, which represents
the majority of AML patients. Preliminary data presented in this proposal describe the identification of 2-
oxoglutarate dehydrogenase (OGDH), a tricarboxylic acid (TCA) cycle enzyme which catalyzes the conversion
of alpha-ketoglutarate (aKG) to succinyl CoA, as a previously unknown metabolic vulnerability in AML. Inhibition
of this enzyme is sufficient to upregulate cellular aKG and drive myeloid differentiation in AML cells lacking IDH
mutations. Currently however, the molecular mechanisms facilitating the change in cell fate with OGDH inhibition
remain unknown, as do the genotypic contexts where exploiting aKG-dependent metabolism is most efficacious.
The studies proposed seek to rigorously test the hypotheses that, 1) the treatment-refractory TP53-
mutant/complex karyotype (CK) AML subset may be particularly sensitive to aKG perturbation, and 2) that the
TET family of aKG-dependent dioxygenases which convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC) and impact gene expression, among other chromatin modifying enzymes, serve as effectors of aKG-
dependent differentiation. The research plan will utilize in vitro systems to characterize the aKG-dependent
epigenetic program, in vivo mouse models to examine OGDH as a putative target in TP53-mutant/CK AML, and
patient samples/patient-derived xenografts to determine if aberrant aKG-dependent metabolism sustains human
leukemia. The proposed investigations will expand our biological understanding of metabolite use in leukemia
and advance a differentiation-based strategy to treat chemotherapy-refractory leukemias that lack conventionally
targetable oncogenes. The applicant, Dr. Scott Millman, an Instructor on the Leukemia Service at the Memorial
Sloan Kettering Cancer Center (MSKCC), has devised a 5-year career development plan that builds upon his
background in molecular biology and biochemistry, and his clinical training in medical oncology. Dr. Millman will
conduct the proposed research under the mentorship of Dr. Scott Lowe, an internationally renowned expert in
cancer genetics with a proven track record of training successful independent investigators, to develop new skills
in functional genomics and leukemia modeling that are essential for his career goal of developing new therapeutic
approaches for hematologic malignancies. This mentorship, combined with the ideal training environment
provided at MSKCC, will allow Dr. Millman to carry out the proposed research program and transition to an R01-
funded independent, physician-scien...

## Key facts

- **NIH application ID:** 10891504
- **Project number:** 5K08CA259453-03
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** Scott Evan Millman
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $206,076
- **Award type:** 5
- **Project period:** 2022-08-17 → 2025-06-13

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10891504

## Citation

> US National Institutes of Health, RePORTER application 10891504, Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia (5K08CA259453-03). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10891504. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*